Evaxion Biotech A/S - ADR EVAX

NAS: EVAX | ISIN: US29970R1059   27/06/2025
2,450 USD (-5,22%)
(-5,22%)   27/06/2025

25 juni 2025 · Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus · Persbericht

3 juni 2025 · Evaxion receives grant funding to design new polio vaccine · Persbericht

27 mei 2025 · Evaxion announces business update and first quarter 2025 financial results · Persbericht

23 mei 2025 · Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025 · Persbericht

22 mei 2025 · Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01 · Persbericht

28 april 2025 · 80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting · Persbericht

10 april 2025 · Evaxion to present at World Vaccine Congress · Persbericht

1 april 2025 · Evaxion announces business update and full year 2024 financial results · Persbericht

27 maart 2025 · Evaxion to announce business update and full year 2024 financial results on April 1, 2025 · Persbericht

25 maart 2025 · Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting · Persbericht

4 maart 2025 · Evaxion to present at numerous upcoming conferences · Persbericht

25 februari 2025 · Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package · Persbericht

14 februari 2025 · Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination · Persbericht

31 januari 2025 · Evaxion announces closing of $10.8 million public offering · Persbericht

30 januari 2025 · Evaxion announces pricing of $10.8 million public offering · Persbericht

28 januari 2025 · Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement · Persbericht

15 januari 2025 · Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01 · Persbericht

14 januari 2025 · Evaxion announces completion of ADS ratio change · Persbericht

10 januari 2025 · Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change · Persbericht

30 december 2024 · Evaxion announces plan to implement ADS ratio change · Persbericht

Mijn selecties